Bone Density After Menopause: Where D3, K2, and Protein Fit
Three nutrients dominate the conversation about bone health after menopause. All three have more complicated evidence than the marketing suggests, and the complications run in different directions.
One has been substantially undercut by large randomized trials and now carries formal recommendations against its routine use for this purpose. One has genuinely mixed trial results. And one spent decades being blamed for harming bone before the research reversed, and now has modestly positive support.
This post covers what the evidence actually shows for each, where the honest limits sit, and what the research consistently identifies as mattering more than any of them.
What happens to bone after menopause
Bone is living tissue in continuous turnover, with osteoclasts breaking down old bone and osteoblasts building new bone. Estrogen plays a regulatory role in keeping that cycle balanced. When estrogen declines through the menopausal transition, resorption begins outpacing formation, and bone density falls.
The result is an accelerated loss that is specific to this period rather than a general feature of aging. It is also the reason bone health becomes a more prominent concern for women in midlife than for men of the same age.
Osteoporosis itself is a clinical diagnosis with defined criteria and established medical treatments. Nothing in this post addresses treatment, and anyone with diagnosed osteoporosis or osteopenia should be working with a physician rather than substituting nutritional strategies for medical care. What follows is about what nutrition contributes, which is a narrower question.
Vitamin D: what the large trials found
This is where the evidence has shifted most dramatically, and where the gap between current guidance and popular assumption is widest.
The VITAL trial is the central piece of evidence. Published by LeBoff and colleagues in the New England Journal of Medicine in 2022, volume 387, issue 4, pages 299 to 309, it was an ancillary study of a two-by-two factorial randomized controlled trial testing supplemental vitamin D3 at 2,000 IU per day against placebo. The ancillary study included 25,871 participants with a mean age of 67, of whom 51 percent were women, drawn from all 50 US states. Participants were men aged 50 and older and women aged 55 and older, and were not recruited on the basis of vitamin D deficiency, low bone mass, or osteoporosis.
The primary endpoints were incident total, nonvertebral, and hip fractures, reported on annual questionnaires and adjudicated by centralized medical record review.
The finding: vitamin D3 supplementation did not result in a significantly lower risk of fractures than placebo.
One detail is worth emphasizing because it preempts the most common objection. The absence of benefit persisted even among participants with lower baseline 25-hydroxyvitamin D concentrations, below 20 nanograms per millilitre. The null result was not simply an artifact of studying an already-replete population.
These findings were corroborated by the DO-HEALTH study in Europe and the D-Health trial in Australia, both of which similarly found no significant reduction in fracture risk among vitamin D-replete older adults.
The accompanying editorial by Cummings and Rosen, published in the same issue, was titled "VITAL findings: A decisive verdict on vitamin D supplementation."
What the guidelines now say
The regulatory and professional response has followed the evidence, and it is more direct than most people realize.
The US Preventive Services Task Force, in its 2024 draft recommendation, issued a grade D statement against vitamin D supplementation for the primary prevention of fractures and falls in community-dwelling adults. A grade D recommendation means the task force recommends against the service, having concluded there is no net benefit or that harms outweigh benefits. The stated reasoning cited potential harms including nephrolithiasis, combined with the absence of net benefit observed in trials such as VITAL, in a largely vitamin D-sufficient population.
The 2024 Endocrine Society Clinical Practice Guideline similarly advises against empiric vitamin D supplementation in healthy adults younger than 75, and discourages routine screening of serum 25-hydroxyvitamin D levels.
Both bodies maintain that supplementation remains appropriate for specific subgroups, including adults aged 75 and older, pregnant individuals, and those at elevated metabolic risk such as people with prediabetes.
The scope of these recommendations matters and should not be overstated in either direction. They address primary prevention in community-dwelling adults without known osteoporosis or established deficiency. They do not address people with diagnosed deficiency, diagnosed osteoporosis, or the specific subgroups named above. Vitamin D remains genuinely necessary for calcium absorption, and correcting a genuine deficiency remains a legitimate clinical intervention.
What has changed is the case for taking vitamin D as a fracture-prevention measure if you are a generally healthy adult without deficiency. That case has weakened substantially.
Vitamin K2: mixed, as covered previously
We have written about vitamin K2 and bone in detail elsewhere, including the trials that disagree, so this will be brief.
The headline evidence is the Knapen trial, published in Osteoporosis International in 2013, a three-year randomized controlled trial in 244 postmenopausal women aged 55 to 65 taking 180 micrograms of MK-7 daily. It found significantly decreased age-related decline in bone mineral density at the lumbar spine and femoral neck, though not at the total hip, and reduced vertebral height loss.
It sits alongside other rigorous trials that found no significant benefit, including a 2010 trial by Emaus and colleagues in 334 Norwegian women using 360 micrograms of MK-7 for one year, a 2020 three-year trial in 142 postmenopausal women with osteopenia using 375 micrograms daily that found no difference from placebo at any measured site, and work by Binkley and colleagues that confirmed vitamin K reduced undercarboxylated osteocalcin as expected while producing no detectable change in bone turnover, density, or geometry.
The mechanism, involving K2-dependent carboxylation of osteocalcin, is well established at the biochemical level. Whether that translates into measurable bone outcomes remains genuinely contested, with well-designed trials reaching opposing conclusions.
Protein: the reversal worth knowing about
Protein has the most interesting history of the three, because the prevailing view was wrong for decades in a specific and identifiable way.
The acid-ash hypothesis held that dietary protein, particularly animal protein, generates an acid load that the body neutralizes by drawing calcium from bone, thereby causing bone loss. It was widely accepted, widely taught, and drove recommendations to limit protein intake for bone health.
A series of analyses by Fenton and colleagues systematically dismantled it. Their 2009 meta-analysis in the Journal of Bone and Mineral Research, volume 24, pages 1835 to 1840, examined the effect of the acid-ash hypothesis on calcium balance. Their 2011 paper in Nutrition Journal, volume 10, article 41, conducted a causal assessment of dietary acid load and bone disease applying Hill's epidemiological criteria for causality. The hypothesis did not survive that scrutiny, and a subsequent meta-analysis found no evidence for a protective effect of an alkaline diet on bone health.
What replaced it is a modestly positive picture, though one with real internal tension worth reporting honestly.
An expert consensus paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases and by the International Osteoporosis Foundation, published in Osteoporosis International in 2018, concluded that in older people with osteoporosis, higher protein intake at or above 0.8 grams per kilogram of body weight per day is associated with higher bone mineral density, a slower rate of bone loss, and reduced risk of hip fracture, provided calcium intake is adequate.
The Health, Aging, and Body Composition Study found that higher protein intake was associated with lower vertebral fracture risk, with the upper protein tertile, averaging 1.1 grams per kilogram per day, showing 1.8 to 6.0 percent higher mean baseline bone mineral density. The authors concluded that the lower end of the acceptable macronutrient distribution range and the 0.8 gram per kilogram RDA may be suboptimal for bone mineral density preservation in older adults. A meta-analysis of cross-sectional studies attributed a 2 to 4 percent increase in bone mineral density to protein intake above the RDA.
Here is the tension. A systematic review and meta-analysis conducted for the National Osteoporosis Foundation and published in the American Journal of Clinical Nutrition pooled six randomized controlled trials and found no difference between higher and lower protein intake on femoral neck bone mineral density, with a pooled mean percentage change of negative 0.14 percent, a 95 percent confidence interval of negative 0.60 to 0.32, and zero statistical heterogeneity.
So the observational and cohort evidence associates higher protein intake with better bone outcomes, particularly fracture risk, while the randomized trial evidence on bone mineral density specifically shows no difference. That pattern can reflect several things: that protein affects fracture risk through pathways other than density, such as muscle mass and fall prevention; that observational associations are confounded by overall dietary quality; or that the RCTs were too short to detect changes in a slow-moving outcome.
The honest reading: protein is not harmful to bone, which was the older belief and was wrong. The evidence that higher intake actively improves bone density in randomized trials is absent. The evidence associating it with lower fracture risk is real but observational.
What the research consistently identifies as mattering more
Across this literature, one intervention appears more consistently than any nutrient, and it is not a supplement.
Weight-bearing and resistance exercise applies mechanical load to bone, and bone responds to mechanical load by remodelling. This is the same principle underlying why astronauts lose bone density in microgravity and why the loading history of a limb affects its density. It is a direct stimulus rather than a supporting input.
There is also a compounding factor specific to fractures rather than density. Most osteoporotic fractures occur as a result of falls. Muscle strength, balance, and reaction time determine fall risk, and all three respond to resistance and balance training. A person with stronger legs and better balance falls less often, and fracture risk is a function of both bone fragility and the frequency of the events that stress it.
This is why interventions combining resistance training with nutritional support consistently outperform nutritional support alone in the broader literature on musculoskeletal outcomes in older adults, a pattern we have examined in detail elsewhere.
The honest hierarchy
Putting this together for bone health after menopause specifically.
Weight-bearing and resistance exercise has the most direct mechanism and the strongest case, both for bone loading and for reducing the falls that convert low bone density into actual fractures.
Adequate calcium intake remains a foundational requirement, and the ESCEO and IOF protein consensus explicitly conditions its findings on adequate calcium.
Adequate protein is supportive and no longer suspect. The old acid-ash concern has been overturned. Higher intake associates with lower fracture risk in cohort data, while randomized trials show no bone density difference. The recommendations at or above 0.8 grams per kilogram per day are reasonable, and overlap with the intake ranges recommended for muscle preservation.
Vitamin D remains necessary for calcium absorption, and correcting a genuine deficiency remains legitimate. Taking it as a fracture-prevention measure without deficiency is not supported by VITAL, DO-HEALTH, or D-Health, and both the USPSTF and the Endocrine Society have issued recommendations reflecting that.
Vitamin K2 has a well-established biochemical mechanism and genuinely contested trial results, with one three-year trial finding site-specific benefits and several equally rigorous trials finding none.
What this means for us
We sell a vitamin D3 and K2 product, and the evidence above complicates the case for it more than it supports it. Stating that plainly is the only defensible option.
For D3, the honest position is that the fracture-prevention rationale does not hold up for generally healthy adults without deficiency, based on trials involving tens of thousands of participants and reflected in current guidance from two major bodies. Vitamin D still has a real physiological role in calcium absorption, deficiency is still worth correcting, and specific populations still warrant supplementation. But if the reason you are taking D3 is to prevent fractures and you are not deficient, the large randomized trials do not support that expectation.
For K2, the position we have held across previous posts stands: promising mechanism, genuinely mixed trial results, not established.
Anyone wanting to know their actual vitamin D status can have it measured, though it is worth noting that the Endocrine Society's 2024 guidance specifically discourages routine screening in healthy adults under 75, which is itself a signal about how the field now views population-wide vitamin D management.
The honest summary
Bone loss accelerates after menopause because estrogen's regulatory role in bone turnover diminishes. That is real and worth taking seriously.
Vitamin D3 supplementation did not reduce fracture risk in VITAL, a trial of 25,871 participants, and the null result held even in those with lower baseline vitamin D levels. DO-HEALTH and D-Health corroborated it. The USPSTF issued a grade D recommendation against supplementation for primary fracture prevention in community-dwelling adults in 2024, and the Endocrine Society advises against empiric supplementation in healthy adults under 75.
Vitamin K2 has a solid biochemical mechanism and contradictory trial results, with rigorous studies on both sides.
Protein is the most improved story: the decades-long belief that it harms bone was overturned by Fenton and colleagues, and current expert consensus associates intake at or above 0.8 grams per kilogram with better bone outcomes, though randomized trials show no bone density difference and the positive findings are observational.
And exercise, specifically weight-bearing and resistance training, remains the intervention with the most direct mechanism and the clearest role, both in loading bone and in reducing the falls that turn low density into fractures.
That is a less supplement-friendly conclusion than most content on this topic reaches. It is what the trials found.
